Neoleukin Therapeutics, Inc. Announced that Jonathan G. Drachman, M.D. will be resigning from his role as President, Chief Executive Officer, principal executive and financial officer, and will also be resigning as a director of the Company, all effective March 31, 2023 (Separation Date). Dr. Drachman's resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.5 USD | -2.14% | -11.27% | +67.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.70% | 418M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neoleukin Therapeutics, Inc. Announces Board Changes